Trial record 9 of 17 for:    "Stuttering"

Follow-up of Children After Stuttering Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by University of Sydney.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Sydney
ClinicalTrials.gov Identifier:
NCT00709072
First received: July 1, 2008
Last updated: April 22, 2010
Last verified: June 2009
  Purpose

This study aims to determine the percentage and predictors of stuttering relapse following treatment with the Lidcombe Program. It will also investigate the effectiveness of sending reminder messages to parents to assist in reducing relapse.


Condition Intervention Phase
Stuttering
Behavioral: SMS (Short Message Service) reminders
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Relapse Following the Lidcombe Program for Preschool Children Who Stutter

Resource links provided by NLM:


Further study details as provided by University of Sydney:

Primary Outcome Measures:
  • percentage of syllables stuttered [ Time Frame: six monthly for three years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • parent reported stuttering severity [ Time Frame: six monthly for three years ] [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: February 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
SMS reminders
Behavioral: SMS (Short Message Service) reminders
SMS reminders sent every 2 weeks
No Intervention: 2
control group

Detailed Description:

Stuttering treatment becomes more time-consuming and less effective as children become older. Therefore it is crucial to prevent relapse following treatment in the early years. This study will investigate predictors of relapse and assess the effectiveness of a simple two-weekly user-friendly reminder to parents, about when and how to address any re-occurring stuttering after treatment. Results from the study may help to prevent stuttering relapse in this age group in the future.

  Eligibility

Ages Eligible for Study:   3 Years to 7 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Completion of stage I of Lidcombe Program
  • Less than 1 percent syllables stuttered at recruitment
  • Means of receiving SMS email or phone reminder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00709072

Locations
Australia, New South Wales
Australian Stuttering Research Centre Recruiting
Sydney, New South Wales, Australia, 1825
Contact: Mark Onslow, PhD    61 2 9351 9061    M.Onslow@usyd.edu.au   
Sponsors and Collaborators
University of Sydney
Investigators
Principal Investigator: Mark Onslow, PhD The University of Sydney
  More Information

No publications provided

Responsible Party: Professor Mark Onslow, The University of Sydney
ClinicalTrials.gov Identifier: NCT00709072     History of Changes
Other Study ID Numbers: 10483
Study First Received: July 1, 2008
Last Updated: April 22, 2010
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by University of Sydney:
stuttering
relapse
Lidcombe Program
Preschool children

Additional relevant MeSH terms:
Stuttering
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 20, 2014